Abstract—Cardiac allograft vasculopathy is the major cause of late graft loss in heart transplant recipients. Histological studies of characteristic end-stage lesions reveal arterial changes consisting of a diffuse, confluent, and concentric intimal expansion containing graft-derived cells expressing smooth muscle markers, extracellular matrix, penetrating microvessels, and a host mononuclear cell infiltrate concentrated subjacent to an intact graft-derived luminal endothelial cell lining with little evidence of acute injury. This intimal expansion combined with inadequate compensatory outward remodeling produces severe generalized stenosis extending throughout the epicardial and intramyocardial arterial tree that causes ischemic graft failure. Cardiac allograft vasculopathy lesions affect ≥50% of transplant recipients and are both progressive and refractory to treatment, resulting in ≥5% graft loss per year through the first 10 years after transplant. Lesions typically stop at the suture line, implicating alloimmunity as the primary driver, but pathogenesis may be multifactorial. Here, we will discuss 6 potential contributors to lesion formation (1) conventional risk factors of atherosclerosis; (2) pre- or peritransplant injuries; (3) infection; (4) innate immunity; (5) T-cell–mediated immunity; and (6) B-cell–mediated immunity through production of donor-specific antibody. Finally, we will consider how these various mechanisms may interact with each other. (Arterioscler Thromb Vasc Biol. 2014;34:1609-1614.)

Key Words: T-lymphocytes transplantation

Cardiac allograft vasculopathy (CAV), a pathological process affecting the vasculature of transplanted hearts, is the major cause of late heart graft failure.1,2 Although changes are found in the blood vascular tree throughout graft, the most clinically relevant feature is the change observed in the arterial circulation, and we will focus this review on these atherosclerotic changes. End-stage lesions (analyzed in failing hearts examined at autopsy or in grafts removed during retransplantation) show extensive, confluent luminal narrowing because of a combination of concentric intimal hyperplasia and inadequate compensation by outward remodeling; the confluent nature of the narrowing has made it difficult to recognize CAV by conventional angiography. Early intimal lesions may be eccentric and focal, but these may be adequately compensated by outward remodeling, again making them difficult to recognize by angiography. Diagnosis, therefore, requires a measure of wall thickness, typically provided by intravascular ultrasound (the current gold standard) or possibly coronary computed tomography.3,4 As the lumen becomes more progressively stenotic, graft failure results from organ hypoperfusion. It is estimated that ≥50% of cardiac allograft recipients develop clinically significant vasculopathy and CAV lesions progress at a rate that causes ≥5% of grafts being lost in each of the first 10 years after transplantation.5

The pathogenesis of CAV inferred from clinical observations has been uncertain.6 Therefore, inferences regarding causality have instead largely been drawn both from analysis of the expanded intima from late-stage human lesions and from animal models, typically involving vascular interposition allografts or heterotopic cardiac allografts.7,8 Because there are profound differences in the manner in which rodents and humans respond to allogeneic blood vessels,9 we will focus our remarks on human tissue analyses and on the human alloresponse to vascular cells studied in vitro or in humanized mouse hosts. The majority of the cells in the expanded intima of human allografts express markers of vascular smooth muscle cells (SMCs).10 These intimal SMCs may arise from any of 5 different sources: (1) human coronary arteries contain resident intimal SMCs and these cells may simply expand in number; (2) SMCs from the media may enter into the intima, undergoing cell division in either compartment to expand in number; (3) intimal SMCs may arise from progenitor cells resident at the medial/adventitial border; (4) SMCs may arise from endothelial mesenchymal transition as occurs in embryonic development of the heart; and (5) circulating host cells may be recruited to the graft vessel wall where they acquire SMC characteristics. It is clear is that the vast majority of intimal SMCs in human allografts are not derived from the host, either from adjacent vessels or from the host circulation.11 The relative contributions of the other 4 sources of SMCs to human CAV lesions are unresolved. The neointima contains considerable extracellular matrix, thought to be produced primarily by the SMCs.
Although graft-derived SMCs and the matrix they produce form the bulk of the expanded intima, they are not the only elements present. The hyperplastic intima of affected vessels remains covered by an intact luminal endothelial cell (EC) lining, which, in the arterial tree, is also of graft and not of host origin. The expanded intima contains microvessels and an infiltrate formed largely of host T cells and macrophages, and a majority of the T cells are memory cells that express interferon-γ (IFN-γ) and transforming growth factor-β. Nodular aggregates of host B cells, T cells, and myeloid cells are commonly found in the adventitia, possibly as part of rudimentary tertiary lymphoid organs associated with chronic inflammation. The media seems generally normal in arteries affected by CAV. Intimal leukocytes tend to be concentrated just subjacent to the EC lining, and most of the SMCs are concentrated near the intimal/medial border. These varied cell populations show little if any evidence of necrosis, but occasional evidence of apoptotic cells, has been reported. Affected arteries also show evidence of EC dysfunction (eg, by failing to dilate in response to acetylcholine). The barrière created by the expanded intima separating the EC lining from the SMCs of the vessel media, as well as potential refractoriness of the medial SMCs to NO, may also contribute to this dysfunction. The extracellular matrix tends to be collagen rich and elastin poor, which also may affect vessel function.

Having described the characteristic features of CAV in the arterial tree, we will focus in the remainder of this Brief Review on potential mechanisms that may contribute to the development of the hyperplastic intima. In a concluding section, we will discuss how these mechanisms may interact.

Conventional Risk Factors of Atherosclerosis

There are points of similarity between arterial changes observed in CAV, sometimes called transplant or graft atherosclerosis, and the more common metabolic/inflammatory disorder of atherosclerosis. For example, early lesions in both cases may involve eccentric formation of a hyperplastic intima that contains SMCs, T cells, macrophages, angiogenic microvessels, and extracellular matrix covered by an intact luminal EC lining. Both processes tend to spare the vessel media and are associated with adventitial inflammation that may take the form of lymphoid nodular aggregates. Finally, both processes are associated with endothelial dysfunction in the form of inadequate vasodilation in response to acetylcholine. However, there are important differences, most notably that the intima of atheromas contains lipid-laden foam cells and a lipid-rich necrotic core, usually absent in CAV, and when these are seen, they may represent pre-existing atheromas that formed in the donor before transplantation. The SMCs in atheromas are concentrated within a fibrous cap subjacent to the EC lining, whereas T cells and macrophages are largely localized to shoulder regions of the lesion as opposed to the organization of CAV, which localizes SMCs to the deeper regions of the intima adjacent to the media and concentrates the inflammatory infiltrate subjacent to the luminal endothelium. These similarities and differences are readily explained if one posits that both processes are driven by adaptive immune responses to antigen, but that the antigens are different (see below for a fuller discussion of adaptive immunity in CAV). Specifically, the principal antigens driving atherosclerosis are likely to be altered (eg, oxidized) low-density lipoproteins that deposit in the extracellular matrix and/or are taken up by macrophages that become foam cells, whereas the principal antigen in the case of CAV are nonself major histocompatibility complex molecules, especially HLA-DR, expressed most abundantly on the luminal EC. This hypothesis explains both the distinct sites of localization of the inflammatory infiltrates and explains why atherosclerosis is a systemic disease and CAV stops at the suture lines separating donor from host.

Although elevated low-density lipoprotein levels are the primary drivers of atherosclerosis, could they contribute to CAV as a secondary driver? Even though the extracellular matrix in CAV is not filled with lipid-rich necrotic cores or foam cells, the lipid content of the intima is often elevated. Medical therapy for primary prevention in atherosclerosis involves the use of statins to reduce hepatic synthesis of cholesterol, resulting in lowered low-density lipoprotein levels when compared with normal intima, and statins have been shown to reduce the incidence of CAV although the effect is small. Moreover, these benefits may relate more to the inhibitory effects that statins have on T cells than on lipid lowering.

Pre- and Perioperative Injuries to Graft Vessels

In renal transplantation, cadaver organs do less well long term than do organs from living donors, a difference attributed to vascular injury during the period of continued perfusion after brain death. Worse outcome is also associated with renal delayed graft function, a manifestation of pretransplant injury. Postcardiac transplant dysfunction also correlates with poor outcome. The link between graft vessel injury and CAV was suggested by the idea that intimal hyperplasia in atherosclerosis may start as a response to injury, but as we have noted above, CAV and atherosclerosis are not the same process. An important consideration is that complement, activated either by natural antibodies or the mannose-binding lectin pathways, has been reported to play a role in ischemia reperfusion injury of various organs and complement, activated by donor-specific antibody (DSA), has been linked to CAV. It is unclear if any of these other initiators of complement activation may also be linked to CAV. Finally, as we will discuss below, ischemia reperfusion injury of resident vascular cells may release molecules that act as stimulators of innate immunity. Although many of these molecules are unknown, injured ECs have been shown to release interleukin-1α (IL-1α), a potent mediator of inflammation and immunity.

Infection

There is considerable evidence that concurrent infection, including infections that do not directly involve the vasculature such as chronic gingivitis, respiratory infections, or gastritis, is a risk factor of atherosclerosis, perhaps by increasing circulating factors that act on the endothelium to promote inflammation. In the case of CAV, only infection by cytomegalovirus is well established as a factor for increased risk. Risk of CAV increases with viral load but even subclinical infection is sufficient to contribute. Furthermore, pre-emptive treatment
of subclinical infection with ganciclovir can reduce (but not eliminate) the risk of developing CAV. Efforts to demonstrate infection of the coronary graft vasculature have generally been negative, and the association of cytomegalovirus with CAV has led to 2 alternative hypotheses. First, some cytomegalovirus component or a host factor generated in response to cytomegalovirus may activate graft endothelium to increase inflammation, similar to the hypothesis linking bacterial infections to atherosclerosis. Second, the presence of cytomegalovirus may alter the host immune system in some unspecified manner that increases the contributions of adaptive immunity (see below) to CAV development. Neither of these ideas has been proven, and it remains unknown how cytomegalovirus infection contributes to the risk of developing CAV.

Innate Immunity

Innate immunity refers to elements of the host defense to microbes that can act independently of lymphocyte populations that require gene rearrangements to generate antigen receptors (ie, T cells, B cells, and NK/T cells). Among the cell types that contribute to innate immunity are both leukocytes and tissue cells. The principal innate leukocytes that have been implicated in the pathogenesis of CAV, based on mouse models of transplant vasculopathy, are NK cells and macrophages. NK cells can recognize allogeneic cells because these cells express germ-line-encoded killer inhibitory receptors that are selected to recognize self-allelic forms of class I HLA antigens, particularly (but not exclusively) HLA-C alleles. This phenomenon, known as activation to absent self, has been shown to play a major role in the rejection of nonself hematopoietic stem cells and their bone marrow–derived progeny but has been considered less important for rejection of solid organ allografts. On activation, NK cells can be a source of cytokines, such as IFN-γ, that can serve as a mitogen for SMCs. Although several recent studies have shown a role for NK cells in murine models of CAV, NK cells seem require the presence of T cells and DSA. In other words, this may not be so much an example of innate immunity but rather an example of how an innate leukocytic effector cells can be co-opted and targeted by the adaptive immune system. Unlike NK cells, macrophages lack receptors that can distinguish self from nonself human cells, but like NK cells, macrophages express Fc receptors capable of binding antibodies and may be targeted to respond to nonself by DSA. Macrophages also express germ-line-encoded pattern recognition receptors that can recognize microbe-derived molecules, known as pathogen-associated molecular patterns not expressed by eukaryotic cells. These same pattern recognition receptors may also enable macrophages to respond to sequestered eukaryotic molecules that have been released and structurally altered as a result of tissue injury (damage-associated molecular patterns). Although allograft vessels are likely to be sterile and devoid of pathogen-associated molecular patterns (unless infected by cytomegalovirus, see above), they may be injured and release pathogen-associated molecular patterns that can activate macrophages to produce mitogens for SMCs. Depletion of macrophages can reduce CAV in mouse models, but the adaptive immune system is intact in these models and activated T cells can serve to direct the macrophage response.

It seems likely that NK cells and macrophages also play a role in human CAV as such cells are present in the lesions in patterns similar to what has been seen in mouse models, but there are no data in humans to support a role for these cells independent of adaptive immunity. In addition to their role as a source of mitogens for SMCs, NK cells and macrophages also release cytokines that cause and direct the activation of T cells. In other words, even if they do not play an independent role in CAV, innate leukocytes may contribute both as modulators and as effectors of T-cell responses. Like macrophages, resident vascular cells express pattern recognition receptors. Consequently, pathogen-associated molecular patterns and damage-associated molecular patterns may also induce these cells to produce cytokines that modulate T-cell responses. ECs, activated through pattern recognition receptors, may also be a source of growth factors for SMCs, contributing to CAV. However, there is no evidence to suggest that CAV can develop in settings in which the adaptive immune system is absent.

T-Cell–Mediated Immunity

Effector T cells mediate host defense via direct cytolysis of infected cells or by elaboration of cytokines that recruit and activate effector cells of innate immunity (such as neutrophils, eosinophils, macrophages, or NK cells). Both functions are triggered by recognition of nonself antigens, generally in the form of nonself peptides, such as those derived from the proteins of a microbe, bound to a self-allelic form of an HLA molecule that is displayed on the surface of another cell. HLA molecules are extremely polymorphic, a feature that not only allows different alleles to bind different peptides but also ensures that every graft, unless from an identical twin, will express HLA molecules not expressed by the host. The actual epitope recognized by the T-cell receptor for antigen is comprised of amino acid residues in the peptide and in the polymorphic peptide binding region of the HLA molecule. Cytolysis is typically mediated by T cells expressing CD8 and recognition involves peptide bound to a class I HLA molecule (HLA-A, B, or C), whereas cytokine-producing effector cells more typically express CD4 and respond to peptides bound to class II HLA molecules (HLA-DR, DP, or DQ). Allorecognition can involve recognition of peptides derived from polymorphic proteins bound to self-allelic major histocompatibility complex molecules displayed on the surface of a host cell (referred to as indirect recognition) or can be a cross reaction in which T cells that normally recognize nonself protein-derived peptides bound to self-HLA molecules instead respond to peptides (which may be self- or nonself derived) bound to nonself HLA molecules (direct recognition) expressed on the surface of a graft cell. The principal cellular target of direct recognition in coronary arteries is the graft EC lining the lumen because these cells express high levels of both class I and class II HLA molecules, whereas graft SMC express only minimal levels of HLA. Because there is little evidence for cytolysis in CAV lesions, the host T cells that are present subjacent to the EC likely function through release of cytokines and an analysis of T cells recovered from lesions reveal that the principal cytokines made by these cells are IFN-γ and transforming growth factor-β.
We have modeled this process by implanting human coronary artery segments into immunodeficient mice along with adoptively transferred T cells from a donor allogeneic to the artery donor. Neutralizing IFN-γ prevents the development of intimal expansion, and addition of human IFN-γ in the absence of T cells induces intimal expansion. In contrast, neutralizing transforming growth factor-β increases cytosis, especially of medial SMC, with little effect on intimal size. Cultured human EC, but not SMC, can directly present nonself HLA molecules to human peripheral blood T cells and induce the production of IFN-γ. On the basis of these observations, we have proposed that IFN-γ, produced by host T cells in the intima that are responding to the HLA antigens expressed on the graft EC, is the driver of CAV. This conclusion is derived from a reductionist model in which human T cells alone can produce CAV-like lesions in vivo, but our data do not exclude the possibility that in patients, NK cells and other lymphocytes or myeloid cells, including macrophages, may also contribute to CAV by secreting IFN-γ or other growth factors. We also cannot exclude the possibility that myeloid cells, such as host macrophages or dendritic cells, may present peptides derived from graft-derived SMC or other cell types, leading to indirect alloreognition.

The failure of conventional immunosuppressive drugs, such as calcineurin inhibitors, mTOR inhibitors, antiproliferative agents, and corticosteroids, that primarily target T cells to prevent CAV is discouraging and suggests that T cells and IFN-γ may not be central to CAV pathogenesis. However, the use of these drugs is limited by their toxicity, as well as by the danger to patients of infection and cancer from overly suppressing the immune system. In other words, the therapeutic window that effectively controls acute rejection without undue risk of infection may not be adequate to suppress T-cell responses that drive CAV. It is also possible that these drugs may themselves contribute to injury of vessel wall cells, leading to release of damage-associated molecular patterns and increased local T-cell responses.

**Donor-Specific Antibody**

Observational studies have established that patients who develop a DSA, typically reactive with a nonself HLA-DQ molecule expressed by graft EC, are at greater risk for developing CAV. Such antibodies typically activate complement via the classical pathway and lead to deposits of C4d on the EC lining graft microvessels observed on endomyocardial biopsy. It seems probable that the same antibodies are binding to and then activating complement is on the EC lining graft arteries, but it is not been possible to examine these in living patients. The binding of mouse antihuman monoclonal antibody to class I HLA molecules can activate certain effector pathways in EC that can promote inflammation independent of complement activation. Repeated injection of one such mouse antihuman antibody (W6/32) into immunodeficient mice bearing human artery interposition grafts can produce CAV-like lesions independent of T cells. It is not clear, however, how this antibody, which is much more strongly

**Figure.** An integrated model of CAV pathogenesis. As depicted in this diagram, the primary event in the development of CAV is host T cell recognition of alloantigens presented by graft endothelial cells (EC) lining the arterial lumen, leading to T cell recruitment and activation within the vessel intima. The activated T cells elaborate cytokines, notably IFN-γ, which acts on the EC to promote further recruitment of T cells and acts upon smooth muscle cells (SMC) to cause proliferation, resulting in intimal expansion and diffuse stenosis characteristic of CAV. IFN-γ (and potentially other cytokines) also activates innate immune leukocytes, such as NK cells and macrophages, to produce additional mitogenic signals that act on SMC. Various established risk factors for CAV enhance the ability of EC to recruit and activate T cells, including cyto- megalovirus (CMV) infection, ischemia/ reperfusion (I/R) injury, innate immune signals, such as damage-associated molecular patterns (DAMPs), and donor-specific antibody (DSA). DSA activates complement, leading to formation of membrane attack complex (MAC) on the EC surface. Some of the signals induced by these risk factors that enhance T cell responses are known, such as release of CMV antigens from CMV-infected cells or cytokines, such as IL-6 or IL-1, from injured EC, but others are yet to be characterized. MAC indicates membrane attack complex; and NK, natural killer.
reactive with EC than SMC, causes SMC proliferation and accumulation in an expanded intima. Our own experience, using a single injection of high titer human anti-HLA antibodies present in presensitized patients on the transplant waiting list, does not produce CAV-like changes in this model. On the basis of mouse models that lack T cells, we suspect that W6/32 antibody functions by recruiting and activating NK cells, which, as we have noted above, are a non–T-cell source of IFN-γ. Antibodies directed against molecules other than HLA may also contribute to CAV. Some of these may detect alloantigens but others (autoantibodies) may react with molecules shared by the graft and host. In particular, there has been a reported correlation with the development of autoantibodies to cardiac myosin. However, it is difficult to understand how this works because the relevant antigen is not expressed in cells of the vessel wall. It has also been reported that natural IgM antibodies that react with leukocytes in graft expressed in cells of the vessel wall. It has also been reported that natural IgM antibodies that react with leukocytes in graft recipients may reduce acute rejection, but the effect of such antibodies on CAV is unknown.

Integrated Model of CAV Pathogenesis

In our view, the primary mediator of CAV is IFN-γ that is produced by infiltrating host T cells. These cells are positioned subjacent to graft EC and are activated by direct recognition of nonself class I (for CD8+ T cells) and class II (for CD4+ T cells) HLA molecules expressed by graft EC. Host myeloid cells may permit cells T cells involved in indirect recognition to participate as well. Graft injury leads to the production of cytokines by injured graft cells that enhance T-cell activation, proliferation, and IFN-γ secretion. In our humanized mouse model, the principal cytokine that exerts this effect is IL-6 although IL-1α, released by injured graft cells as a damage-associated molecular pattern, may contribute as well.49 The presence of cytomegalovirus in the recipient will increase the number of T cells that can be activated by EC by responding to cytomegalovirus antigens acquired and then presented by EC. Host myeloid cells and macrophages may contribute to the response by acting as a source of IFN-γ or by producing other growth factors that positively interact with IFN-γ. Innate leukocytic effector cells may also produce cytokines, such as IL-1β or IL-6, that boost T-cell responses. CSA can further contribute by activating NK cells or macrophages via Fc receptors and, as we have recently shown, by enhancing the immunogenic properties of EC in a response mediated by complement membrane attack complex and new EC gene expression downstream of activation of noncanonical NF-κB (nuclear factor-kappa B) signaling.53 These ideas are summarized in the Figure. Finally, we acknowledge that such a unifying hypothesis is likely to be an overly simplistic explanation for what is probably a complicated and multifactorial process. Nevertheless, this idea presents a way forward to develop new therapeutic approaches to what is currently an intractable disease. For example, if effector T cells responding to graft EC are the major drivers of CAV, then neutralizing IFN-γ54 or reducing effector T-cell activation by induction of inhibitory signals on the EC, such as PD-1 ligands, or depriving them of activating signals by preventing complement activation55,56 or by adoptively transferring regulatory T cells could all be developed as new therapeutic approaches.


Interacting Mechanisms in the Pathogenesis of Cardiac Allograft Vasculopathy
Jordan S. Pober, Dan Jane-wit, Lingfeng Qin and George Tellides

Arterioscler Thromb Vasc Biol. 2014;34:1609-1614; originally published online June 5, 2014;
doi: 10.1161/ATVBAHA.114.302818
Arteriosclerosis, Thrombosis, and Vascular Biology is published by the American Heart Association, 7272
Greenville Avenue, Dallas, TX 75231
Copyright © 2014 American Heart Association, Inc. All rights reserved.
Print ISSN: 1079-5642. Online ISSN: 1524-4636

The online version of this article, along with updated information and services, is located on the
World Wide Web at:
http://atvb.ahajournals.org/content/34/8/1609

Permissions: Requests for permissions to reproduce figures, tables, or portions of articles originally published
in Arteriosclerosis, Thrombosis, and Vascular Biology can be obtained via RightsLink, a service of the
Copyright Clearance Center, not the Editorial Office. Once the online version of the published article for
which permission is being requested is located, click Request Permissions in the middle column of the Web
page under Services. Further information about this process is available in the Permissions and Rights
Question and Answer document.

Reprints: Information about reprints can be found online at:
http://www.lww.com/reprints

Subscriptions: Information about subscribing to Arteriosclerosis, Thrombosis, and Vascular Biology is online
at:
http://atvb.ahajournals.org//subscriptions/